A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: The STEADFAST study

Vascular Health and Risk Management

Volumn 10, Issue , 2014, Pages 319-326

  Hassanein, Mohamed ^a   Abdallah, Khalifa ^b   Schweizer, Anja ^c  

^a BETSI CADWALADR UNIVERSITY HEALTH BOARD   (United Kingdom)

^b Alexandria University   (Egypt)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dipeptidyl peptidase 4; Fasting; Hypoglycemia; Incretin; Ramadan; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; HEMOGLOBIN A1C; METFORMIN; VILDAGLIPTIN;

ARTICLE; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIZZINESS; DOCTOR PATIENT RELATION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RELIGION; TREATMENT OUTCOME; WEIGHT CHANGE;

DIPEPTIDYL PEPTIDASE 4; FASTING; HYPOGLYCEMIA; INCRETIN; RAMADAN; TYPE 2 DIABETES MELLITUS;

ADAMANTANE; ASIA; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY WEIGHT; COUNSELING; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; EUROPE; FASTING; FEMALE; GLICLAZIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; ISLAM; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MIDDLE EAST; NITRILES; OFFICE VISITS; PYRROLIDINES; RELIGION AND MEDICINE; TELEPHONE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901709045     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S64038     Document Type: Article

References (25)

1. Ahrén B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13(9):775-783.
2. Ahrén B, Schweizer A, Dejager S, etal. Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(4):1236-1243.
3. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes. Diabetes Obes Metab. Epub February 26, 2014.
4. Farngren J, Persson M, Schweizer A, Foley JE, Ahrén B. Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. J Clin Endocrinol Metab. 2012;97(10):3799-3806.
5. Christensen M, Vedtofte L, Holst JJ, Vilsbøll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes. 2011;60(12):3103-3109.
6. Schweizer A, Dejager S, Foley JE, Shao Q, Kothny W. Clinical experience with vildagliptin in the management of type 2 diabetes in a patient population $75 years: a pooled analysis from a database of clinical trials. Diabetes Obes Metab. 2011;13(1):55-64.
7. Al-Arouj M, Assaad-Khalil S, Buse J, etal. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33(8):1895-1902.
8. Salti I, Bénard E, Detournay B, etal; EPIDIAR study group. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27(10):2306-2311.
9. Aravind SR, Al Tayeb K, Ismail SB, et al; 2009 Ramadan Study Group. Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Curr Med Res Opin. 2011;27(6):1237-1242.
10. Schernthaner G, Grimaldi A, Di Mario U, etal. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest. 2004;34(8):535-542.
11. Tayek J. SUR receptor activity vs incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics. Diabetes Obes Metab. 2008;10(11):1128-1129.
12. Schweizer A, Halimi S, Dejager S. Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan. Vasc Health Risk Manag. 2014;10:15-24.
13. Hassanein M, Hanif W, Malik W, etal. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27(7):1367-1374.
14. Al-Arouj M, Hassoun AA, Medlej R, etal. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract. 2013;67(10): 957-963.
15. Bravis V, Hui E, Salih S, Mehar S, Hassanein M, Devendra D. Ramadan Education and Awareness in Diabetes (READ) programme for Muslims with Type 2 diabetes who fast during Ramadan. Diabet Med. 2010;27(3):327-331.
16. Devendra D, Gohel B, Bravis V, etal. Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract. 2009;63(10):1446-1450.
17. Bolli GB, Tsalikian E, Haymond MW, Cryer PE, Gerich JE. Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions. J Clin Invest. 1984;73(6):1532-1541.
18. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab. 1999;84(9): 3140-3145.
19. Ahrén B, Foley JE, Ferrannini E, etal. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2010;33(4):730-732.
20. Lafeuille MH, Grittner AM, Gravel J, etal. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014;20(Suppl 1):s5-s15.
21. Al Sifri S, Basiounny A, Echtay A, et al; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011;65(11):1132-1140.
22. Aravind SR, Ismail SB, Balamurugan R, etal. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study. Curr Med Res Opin. 2012;28(8):1289-1296.
23. Scherbaum WA, Schweizer A, Mari A, etal. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114-1124.
24. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167-174.
25. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27(3):318-326.